查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1760899

全球性行為感染傳染病（STD）藥物市場

Sexually Transmitted Diseases (STDs) Drug
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球性行為感染傳染病 (STD) 藥物市場規模將達到 1,236 億美元

全球性行為感染傳染病 (STD) 藥物市場規模預計在 2024 年為 722 億美元，到 2030 年將達到 1,236 億美元，在 2024-2030 年的分析期內，複合年成長率為 9.4%。 HPV 是本報告分析的細分市場之一，預計其複合年成長率為 9.8%，到分析期結束時規模將達到 743 億美元。披衣菌感染細分市場在分析期間的複合年成長率預計為 8.7%。

美國市場規模估計為 191 億美元，中國市場預計複合年成長率為 12.9%

2024年，美國性行為感染(STD) 藥物市場規模估計為191億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到274億美元，在2024-2030年的分析期內，複合年成長率為12.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為6.9%和7.2%。在歐洲，預計德國市場的複合年成長率約為7.2%。

全球性行為感染傳染病（STD）藥物市場－主要趨勢與促進因素摘要

什麼是性行為感染傳染病 (STD) 藥物？為什麼它們在現代醫療保健中很重要？

性行為感染傳染病 (STD)，也稱為性感染疾病(STI)，是主要透過性接觸傳播的感染疾病。常見的 STD 包括披衣菌感染、淋病、梅毒、生殖器皰疹、人類乳突病毒 (HPV) 和 HIV/AIDS。用於治療這些感染疾病的藥物種類繁多，包括抗真菌藥物和抗逆轉錄病毒藥物，每種藥物都針對特定的病原體或與疾病相關的症狀。 STD 藥物在控制這些感染疾病、降低感染率和預防長期健康併發症（如不孕症、器官損害和增加對其他感染疾病的易感性）方面發揮關鍵作用。及時有效地治療 STD 對於遏制這些疾病的傳播和改善公共衛生結果至關重要。

由於感染率上升和人們對性健康的認知不斷提高，全球性傳染病藥物市場變得越來越重要。世界衛生組織 (WHO) 估計，全世界每天有超過 100 萬人感染性傳染病，凸顯了對有效治療和預防策略的迫切需求。高風險行為的盛行、性健康教育的不足以及某些地區獲得醫療保健服務的機會有限進一步推動了市場的發展。此外，正在進行的生產更有效、抗藥性更低的藥物的研究和開發也促進了市場擴張。隨著新的抗藥性細菌和病毒株的出現，開發創新治療方法變得比以往任何時候都更加重要。因此，性傳染病藥物市場將在應對全球性行為感染負擔和促進全球性健康方面發揮關鍵作用。

科技進步如何影響治療性病的藥物的發展？

科技進步顯著促進了性傳染病藥物的研發和療效，從而能夠研發出副作用更少、療效更佳的治療方法。該領域的一項重大進展是開發針對抗藥性病原體的新一代抗生素和抗病毒藥物。抗藥性是治療淋病和梅毒等細菌性性傳染病的一大挑戰。多重抗藥性菌株的出現使得許多傳統抗生素失效，因此亟需開發能夠克服抗藥性機制的新型藥物。研究人員正在探索新的抗生素組合和新的藥物輸送系統，例如基於奈米顆粒的製劑，以提高藥物滲透性和對抗抗藥性細菌的療效。這些創新對於維持性傳染病治療的有效性和遏制抗藥性感染的傳播至關重要。

另一項重大進展是標靶治療和個人化醫療方法在性傳染病（STD）治療中的應用。隨著我們對各種感染疾病分子機制的理解不斷加深，研究人員正在開發特異性針對參與病原體複製和存活的蛋白質和路徑的藥物。例如，抑制特定病毒酶活性的標靶抗病毒療法，例如用於治療HIV的蛋白酶抑制劑和用於治療皰疹的解旋酶抑制劑，提供了更有效、更有針對性的治療方案。此外，CRISPR-Cas9等基因編輯技術的進步，透過直接靶向和修改宿主細胞內的病毒DNA，為治癒病毒感染開闢了新的可能性。儘管這些技術仍處於研究的早期階段，但它們有可能改變HIV和皰疹等慢性病毒感染疾病的治療模式。

此外，長效製劑和單劑量治療的開發正在提高患者的依從性和便利性。長效注射劑，例如用於預防和治療愛滋病毒的卡博特韋，可以將給藥頻率從每天減少到每月甚至每季度，使患者更容易堅持治療方法。針對某些細菌性性傳染病的單劑量治療，例如用於治療披衣菌感染的阿奇黴素，為控制感染疾病提供了一種方便有效的解決方案，特別是在醫療保健機會有限的地區。這些技術和科學進步不僅提高了性傳染病治療的有效性和便利性，而且還擴大了醫療保健提供者可用的治療選擇範圍，為性性行為感染患者提供更全面和個人化的護理鋪平了道路。

哪些因素推動了不同地區和族群採用性病藥物治療？

性傳染病藥物的採用受到多種關鍵因素的推動，包括感染率上升、認知和檢測的加強以及全球衛生舉措的實施。其中一個關鍵促進因素是全球性傳染病盛行率上升，尤其是在年輕人和高風險族群中。性行為的變化，例如性伴侶增加和避孕器使用不堅持，正在加劇性傳染病的傳播。為此，醫療保健提供者和公共衛生機構優先考慮使用有效的性傳染病藥物，以遏制感染的傳播並減輕醫療保健系統的負擔。此外，人們對定期性傳染病檢測的認知和接受度不斷提高也支持了感染的早期診斷和治療，從而導致對性傳染病藥物的需求增加。這種趨勢在北美和歐洲等已開發地區尤其明顯，這些地區開展了廣泛的篩檢計劃和宣傳宣傳活動，鼓勵個人及時尋求治療。

推動性傳染病藥物普及的另一個重要因素是旨在降低性傳染病盛行率和改善治療可近性的全球衛生計劃的實施。世界衛生組織和聯合國愛滋病規劃署等治療組織正積極致力於遏制性傳染病的傳播，例如透過《全球衛生部門性行為感染傳染病舉措》和愛滋病毒治療與預防「90-90-90」目標等措施。這些項目強調檢測、治療和預防的重要性，並提供資金和資源以改善治療可近性，尤其是在中低收入國家。因此，更多人能夠獲得診斷服務和救命藥物，促進了這些地區性傳染病藥物的普及。此外，學名藥供應的日益充足也使治療費用更加可負擔，進一步鼓勵了資源匱乏地區的性傳染病患者採用該藥物。

此外，人們日益關注預防性療法，例如用於預防愛滋病毒的暴露前預防 (PrEP)，這也推動了對性傳染病藥物的需求。 PrEP 是一種定期服用抗逆轉錄病毒藥物來預防愛滋病毒感染的方法，它已成為高風險族群中一種有效的預防策略，越來越受歡迎。 PrEP 在減少新的愛滋病毒感染方面的成功促使許多國家採用它，製藥公司也對此做出了回應，開發了療效更好、更方便的新型 PrEP 製劑。這種預防措施不僅限於愛滋病毒，還透過開發疫苗和預防性治療應用於其他性傳染病。例如， 人類乳突病毒(HPV)疫苗可以預防與生殖器濕疣和子宮頸癌相關的某些人類乳突病毒株，已被廣泛用作預防措施。這種預防策略是對傳統治療方法的補充，透過降低感染疾病發生率和促進更好的性健康結果，促進了整個性傳染病藥物市場的成長。

是什麼推動了全球性病市場的成長？

全球性傳染病藥物市場的成長受到多種因素的推動，包括全球感染率上升、研發投入增加以及對解決抗藥性的日益關注。主要成長要素之一是全球性傳染病盛行率的上升。世界衛生組織估計，每年有超過 3.76 億例可治療性傳染病（披衣菌感染、淋病、梅毒、滴蟲病等）新發病例。這些感染疾病會導致併發症並造成負擔，增加了對有效治療的需求。此外，皰疹和愛滋病毒/愛滋病等病毒性性傳染病的盛行率不斷上升進一步促進了市場的成長。隨著性傳染病數量的持續上升，醫療保健提供者和政府正在投資擴大檢測和治療服務的涵蓋範圍，這反過來又推動了對性傳染病藥物的需求。

市場成長的另一個主要驅動力是製藥公司和研究機構不斷增加的研發投入。隨著人們對淋病等細菌性性傳染病抗生素抗藥性的擔憂日益加劇，迫切需要新的有效治療方案。製藥公司正在積極開發新型抗生素，並探索新的作用機制來應對抗藥性菌株。此外，長效製劑和聯合治療的研究正在提供新的治療選擇，以提高患者的依從性並降低抗藥性風險。性傳染病疫苗的開發，例如正在進行的皰疹和愛滋病毒疫苗研究，也透過擴大預防療法的範圍促進了市場發展。此外，遠端醫療平台和家用檢測套組等數位健康技術的整合，正在提高治療的可近性，促進早期診斷和治療，從而支持整個性傳染病藥物市場的成長。

此外，對改善性健康和減少圍繞性傳染病的恥辱感的關注也在推動市場成長。公共衛生宣傳活動和宣傳工作提高了人們對定期篩檢、安全性行為和及時治療重要性的認知，鼓勵更多人尋求治療。這種態度的轉變正在推動對性傳染病藥物的需求，特別是在感染率高的地區。此外，學名藥的出現使得性傳染病藥物更容易取得且價格更實惠，有助於打開已開發經濟體和新興經濟體的市場。隨著這些因素持續影響全球醫療保健格局，性傳染病藥物市場預計將因感染率上升、研發工作持續進行以及全球為改善治療和預防選擇可及性而做出的不斷努力而持續成長。

部分

疾病類型（HPV、披衣菌感染、HIV/AIDS、淋病、生殖器皰疹、梅毒、其他疾病類型）、治療方法（抗生素、抗病毒/抗逆轉錄病毒、疫苗、其他治療方法）

調查企業範例（共46家企業）

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP16773

Global Sexually Transmitted Diseases (STDs) Drug Market to Reach US$123.6 Billion by 2030

The global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$72.2 Billion in the year 2024, is expected to reach US$123.6 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. HPV, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$74.3 Billion by the end of the analysis period. Growth in the Chlamydia segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.1 Billion While China is Forecast to Grow at 12.9% CAGR

The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$19.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.4 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Sexually Transmitted Diseases (STDs) Drug Market - Key Trends & Drivers Summarized

What Are Sexually Transmitted Diseases (STDs) Drugs and Why Are They Critical in Modern Healthcare?

Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), are infections that are primarily spread through sexual contact. Common STDs include chlamydia, gonorrhea, syphilis, genital herpes, human papillomavirus (HPV), and HIV/AIDS. The treatment of these infections relies on a range of pharmaceutical drugs, including antibiotics, antivirals, antifungals, and antiretrovirals, each designed to target specific pathogens or symptoms associated with the disease. STD drugs play a crucial role in managing these infections, reducing transmission rates, and preventing long-term health complications such as infertility, organ damage, or increased susceptibility to other infections. Timely and effective treatment of STDs is essential for controlling the spread of these diseases and improving public health outcomes.

The global STD drugs market is becoming increasingly significant due to rising infection rates and growing awareness of sexual health. The World Health Organization (WHO) estimates that over 1 million STIs are acquired daily worldwide, highlighting the urgent need for effective treatment and prevention strategies. The market is further driven by the increasing prevalence of high-risk behaviors, inadequate sexual health education, and limited access to healthcare services in certain regions. In addition, the ongoing research and development efforts to create more effective and less resistant drugs are contributing to the expansion of the market. With the emergence of new drug-resistant strains of bacteria and viruses, the development of innovative therapies is becoming more critical than ever. As a result, the STD drugs market is poised to play a pivotal role in combating the global burden of sexually transmitted infections and promoting better sexual health worldwide.

How Are Technological and Scientific Advancements Shaping the Development of STD Drugs?

Technological and scientific advancements are significantly enhancing the development and efficacy of STD drugs, enabling the creation of more effective treatments with fewer side effects. One of the key advancements in this field is the development of next-generation antibiotics and antivirals that target drug-resistant strains of pathogens. Drug resistance has become a major challenge in the treatment of bacterial STDs such as gonorrhea and syphilis. The emergence of multi-drug-resistant strains has rendered many traditional antibiotics ineffective, necessitating the development of new classes of drugs that can overcome resistance mechanisms. Researchers are exploring new antibiotic combinations, as well as novel drug delivery systems such as nanoparticle-based formulations, to improve drug penetration and effectiveness against resistant bacteria. These innovations are crucial for maintaining the effectiveness of STD treatments and reducing the spread of resistant infections.

Another significant advancement is the use of targeted therapies and personalized medicine approaches in STD treatment. With a deeper understanding of the molecular mechanisms underlying various infections, researchers are developing drugs that specifically target the proteins or pathways involved in the replication and survival of the pathogens. For instance, targeted antiviral therapies that inhibit the activity of specific viral enzymes, such as protease inhibitors for HIV or helicase inhibitors for herpes, are providing more effective and focused treatment options. In addition, advancements in gene editing technologies, such as CRISPR-Cas9, are opening up new possibilities for curing viral infections by directly targeting and modifying viral DNA within host cells. Although these technologies are still in the early stages of research, they hold the potential to revolutionize the treatment landscape for chronic viral infections such as HIV and herpes.

Furthermore, the development of long-acting formulations and single-dose treatments is enhancing patient compliance and convenience. Long-acting injectables, such as cabotegravir for HIV prevention and treatment, offer the potential to reduce the frequency of dosing from daily to monthly or even quarterly, making it easier for patients to adhere to their treatment regimens. Single-dose treatments for certain bacterial STDs, such as azithromycin for chlamydia, provide a convenient and effective solution for managing infections, particularly in regions with limited access to healthcare. These technological and scientific advancements are not only improving the effectiveness and convenience of STD treatments but are also expanding the scope of therapeutic options available to healthcare providers, paving the way for more comprehensive and personalized care for individuals affected by sexually transmitted infections.

What Factors Are Driving the Adoption of STD Drugs Across Different Regions and Populations?

The adoption of STD drugs is being driven by several key factors, including rising infection rates, increased awareness and testing, and the implementation of global health initiatives. One of the primary drivers is the rising incidence of STDs globally, particularly among young adults and high-risk populations. Changes in sexual behaviors, such as increased number of sexual partners and inconsistent use of protection, are contributing to the spread of STDs. In response, healthcare providers and public health organizations are prioritizing the use of effective STD drugs to control the spread of infections and reduce the burden on healthcare systems. The growing awareness and acceptance of regular STD testing are also supporting the early diagnosis and treatment of infections, leading to higher demand for STD drugs. This trend is particularly noticeable in developed regions such as North America and Europe, where extensive screening programs and awareness campaigns are encouraging individuals to seek timely treatment.

Another significant factor driving the adoption of STD drugs is the implementation of global health initiatives aimed at reducing the prevalence of STDs and improving access to treatment. Organizations such as the WHO and UNAIDS are actively working to combat the spread of STDs through initiatives like the Global Health Sector Strategy on Sexually Transmitted Infections and the “90-90-90” targets for HIV treatment and prevention. These programs emphasize the importance of testing, treatment, and prevention, and they provide funding and resources to improve access to care, particularly in low- and middle-income countries. As a result, more people are gaining access to diagnostic services and life-saving medications, contributing to the growing adoption of STD drugs in these regions. Moreover, the increasing availability of generic drugs is making treatment more affordable, further supporting adoption in resource-limited settings.

Additionally, the rising focus on preventive therapies, such as pre-exposure prophylaxis (PrEP) for HIV prevention, is driving demand for STD drugs. PrEP, which involves taking antiretroviral drugs regularly to prevent HIV infection, is gaining popularity as an effective prevention strategy among high-risk populations. The success of PrEP in reducing new HIV infections is encouraging its adoption in many countries, and pharmaceutical companies are responding by developing new PrEP formulations with improved efficacy and convenience. This focus on prevention is not limited to HIV but is also being applied to other STDs through the development of vaccines and prophylactic treatments. For example, the HPV vaccine, which prevents certain strains of the human papillomavirus linked to genital warts and cervical cancer, is being widely adopted as a preventive measure. These preventive strategies are complementing traditional treatment approaches and contributing to the overall growth of the STD drugs market by reducing the incidence of infections and promoting better sexual health outcomes.

What Is Driving the Growth of the Global STD Drugs Market?

The growth in the global STD drugs market is driven by several factors, including rising global infection rates, increasing investments in research and development, and the growing focus on addressing drug resistance. One of the primary growth drivers is the rising prevalence of STDs worldwide. The WHO estimates that there are over 376 million new cases of curable STDs (such as chlamydia, gonorrhea, syphilis, and trichomoniasis) annually. The high burden of these infections, coupled with their potential complications, is driving the demand for effective treatments. Additionally, the increasing incidence of viral STDs such as herpes and HIV/AIDS is further contributing to market growth. As the number of people affected by STDs continues to rise, healthcare providers and governments are investing in expanding access to testing and treatment services, which is boosting the demand for STD drugs.

Another significant driver of market growth is the increasing investment in research and development by pharmaceutical companies and research institutions. With the growing concern over antibiotic resistance in bacterial STDs like gonorrhea, there is a pressing need for new and effective treatment options. Pharmaceutical companies are actively developing new antibiotics and exploring novel mechanisms of action to address resistant strains. Additionally, research into long-acting formulations and combination therapies is providing new treatment options that improve patient adherence and reduce the risk of resistance. The development of vaccines for STDs, such as ongoing research into vaccines for herpes and HIV, is also contributing to market growth by expanding the scope of preventive therapies. Furthermore, the integration of digital health technologies, such as telemedicine platforms and at-home testing kits, is enhancing access to care and facilitating early diagnosis and treatment, supporting the overall growth of the STD drugs market.

Moreover, the focus on improving sexual health and reducing stigma around STDs is driving market growth. Public health campaigns and advocacy efforts are raising awareness of the importance of regular screening, safe sexual practices, and timely treatment, encouraging more people to seek care. This shift in attitudes is increasing the demand for STD drugs, particularly in regions with high infection rates. Additionally, the availability of generic and over-the-counter (OTC) treatments is making STD drugs more accessible and affordable, supporting market growth in both developed and developing regions. As these factors continue to shape the global healthcare landscape, the STD drugs market is expected to experience sustained growth, driven by rising infection rates, ongoing research and development, and increasing efforts to improve access to treatment and prevention options worldwide.

SCOPE OF STUDY:

The report analyzes the Sexually Transmitted Diseases (STDs) Drug market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital Herpes, Syphilis, Other Disease Types); Therapy (Antibiotics, Antivirals / Antiretrovirals, Vaccines, Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sexually Transmitted Diseases (STDs) Drug - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of STDs Globally Spurs Demand for Effective Therapeutics
    • Increasing Awareness and Early Diagnosis of STDs Expands Addressable Market for Drug Therapies
    • Rising Government and NGO Efforts for STD Prevention Bodes Well for Market Growth
    • Development of Innovative Antibiotics and Antivirals Propels Market Growth for STD Drugs
    • Focus on Addressing Antibiotic Resistance Issues in STD Treatment Supports Market Expansion
    • Emergence of Vaccines for STDs Creates New Opportunities in the Market
    • Focus on Reducing Stigma and Improving Access to Treatment Propels Market Demand
    • Increased Availability of Over-the-Counter STD Treatment Options Bodes Well for Market Growth
    • Rising Demand for Home-Based and Rapid Diagnostic Kits Supports Growth of STD Drug Market
    • Focus on Digital Health Platforms and Telemedicine for STD Treatment Drives Market Growth
    • Emergence of Long-Acting Injectables and Implants Creates New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sexually Transmitted Diseases (STDs) Drug Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for HIV / AIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Genital herpes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Antivirals / Antiretrovirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • JAPAN
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CHINA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • EUROPE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • FRANCE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • GERMANY
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • INDIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AFRICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION